Hims & Hers Health, Inc. HIMS
We take great care to ensure that the data presented and summarized in this overview for Hims & Hers Health, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding HIMS
View all-
Vanguard Group Inc Valley Forge, PA18.2MShares$486 Million0.01% of portfolio
-
Black Rock Inc. New York, NY14.6MShares$388 Million0.01% of portfolio
-
New View Hms Spv Partners, LLC Burlingame, CA9.66MShares$257 Million100.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny5.39MShares$144 Million0.16% of portfolio
-
State Street Corp Boston, MA4.63MShares$123 Million0.0% of portfolio
-
Institutional Venture Management Xvi, LLC Menlo Park, CA4.35MShares$116 Million92.99% of portfolio
-
Geode Capital Management, LLC Boston, MA4.29MShares$114 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA3.44MShares$91.7 Million0.01% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL3.42MShares$91 Million0.02% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.9MShares$77.3 Million0.01% of portfolio
Latest Institutional Activity in HIMS
Top Purchases
Top Sells
About HIMS
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care. The company's curated non-prescription products include vitamin C, melatonin, biotin, and collagen protein supplements in the wellness category; moisturizer, serums, and face wash in the skincare category; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. In addition, it offers medical consultation services, as well as health and wellness products through wholesale partners. The company is based in San Francisco, California.
Insider Transactions at HIMS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 27
2024
|
Melissa Baird Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
31,518
+2.17%
|
$94,554
$3.72 P/Share
|
|
Dec 26
2024
|
Oluyemi Okupe Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,213
-3.18%
|
$122,177
$29.98 P/Share
|
|
Dec 24
2024
|
Michael Chi Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
17,303
-8.2%
|
$467,181
$27.97 P/Share
|
|
Dec 24
2024
|
Michael Chi Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,303
+7.58%
|
$86,515
$5.01 P/Share
|
|
Dec 20
2024
|
Oluyemi Okupe Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
18,959
-3.28%
|
$473,975
$25.76 P/Share
|
|
Dec 19
2024
|
Michael Chi Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
7,500
-3.73%
|
$195,000
$26.0 P/Share
|
|
Dec 19
2024
|
Michael Chi Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+3.6%
|
$97,500
$13.9 P/Share
|
|
Dec 17
2024
|
Andrew Dudum Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
79,246
-44.02%
|
$2,535,872
$32.32 P/Share
|
|
Dec 17
2024
|
Irene Becklund PAO |
SELL
Open market or private sale
|
Direct |
10,012
-57.77%
|
$320,384
$32.2 P/Share
|
|
Dec 17
2024
|
Michael Chi Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
25,550
-11.66%
|
$817,600
$32.2 P/Share
|
|
Dec 16
2024
|
Andrew Dudum Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
78,127
-14.13%
|
$2,265,683
$29.2 P/Share
|
|
Dec 16
2024
|
Andrew Dudum Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
75,335
+15.0%
|
$150,670
$2.43 P/Share
|
|
Dec 16
2024
|
Andrew Dudum Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
47,534
-4.25%
|
$1,378,486
$29.34 P/Share
|
|
Dec 16
2024
|
Irene Becklund PAO |
SELL
Open market or private sale
|
Direct |
472
-2.65%
|
$13,688
$29.58 P/Share
|
|
Dec 16
2024
|
Irene Becklund PAO |
BUY
Exercise of conversion of derivative security
|
Direct |
472
+2.58%
|
$4,248
$9.41 P/Share
|
|
Dec 13
2024
|
Andrew Dudum Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
97,062
-46.26%
|
$2,911,860
$30.02 P/Share
|
|
Dec 13
2024
|
Andrew Dudum Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
176,308
+45.66%
|
-
|
|
Dec 13
2024
|
Melissa Baird Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
28,778
-4.09%
|
$863,340
$30.02 P/Share
|
|
Dec 13
2024
|
Melissa Baird Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
73,146
+9.41%
|
-
|
|
Dec 13
2024
|
Oluyemi Okupe Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
51,573
-25.39%
|
$1,547,190
$30.02 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 115K shares |
|---|---|
| Exercise of conversion of derivative security | 7.56M shares |
| Payment of exercise price or tax liability | 950K shares |
|---|---|
| Open market or private sale | 7.87M shares |
| Bona fide gift | 10K shares |